Summary & Overview
HCPCS Q2034: Influenza Virus Vaccine, Split Virus, Intramuscular
HCPCS Level II code Q2034 identifies the influenza virus vaccine, split virus, for intramuscular use (agriflu). This national-level vaccine code is used to bill for the product itself and is a key element in tracking influenza immunization supply, reimbursement, and public health vaccination efforts. Influenza vaccination remains a core preventive service with broad implications for seasonal disease control and health system capacity.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for Q2034, guidance on where the service is typically delivered, and what to expect in payer coverage patterns. The publication covers benchmark topics such as typical billing practice for vaccine products, payer coverage considerations, and policy or coding updates that could affect product billing. It also outlines common administrative considerations for outpatient vaccination settings.
Where specific input data was not provided, the report notes that information is not available. The content is intended to inform billing administrators, revenue cycle staff, and policy analysts about the clinical identity and billing context of HCPCS Level II code Q2034 at a national level.
Billing Code Overview
HCPCS Level II code Q2034 represents the influenza virus vaccine, split virus, for intramuscular use (agriflu). This code describes a packaged vaccine product intended for intramuscular administration to prevent seasonal influenza.
Service type: Vaccine administration (intramuscular)
Typical site of service: Clinic, physician office, pharmacy, public health clinic, or other outpatient vaccination settings
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 68-year-old patient presents to a primary care clinic during influenza season requesting routine vaccination. The clinician confirms the patient’s immunization history, screens for contraindications (egg allergy, prior severe reaction to influenza vaccine, current moderate or severe acute illness), documents informed consent, and administers the vaccine intramuscularly in the deltoid using Q2034 (influenza virus vaccine, split virus, for intramuscular use - agriflu). The vaccine is supplied as a single-dose prefilled syringe and billed as a HCPCS Level II product. Typical workflow steps include patient registration and verification of insurance, review of immunization registry, clinical screening and counseling, preparation of the vaccine, administration with aseptic technique, 15 minutes post-vaccination observation for syncope or allergic reaction (longer if history of prior reactions), documentation in the medical record and immunization information system, and submission of the claim with applicable modifier(s) and diagnosis code indicating immunization or status.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier; standard service | Use when no special circumstances apply and vaccine is administered per routine protocol. |